Audit: QRS - Black Seed Oil for Health & Longevity

Audit conducted on 23/09/2026 12:35 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	94
Passed	88
Failed	0
N/A	6
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template spans present (marker_# and qualitative_item_# expanded).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	🟢
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.3	[at_a_glance] is no longer than 70 words	🟢	70 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty (7 items).

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty (11 items).

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER Therapeutic Protocol provides more than three actionable aspects; all three sets used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER provides three distinct time-to-effect aspects (blood pressure, glucose/lipids, osteoarthritis pain).
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER Practical Considerations provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers have items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	Risks High empty per ER (“No risk reaches High”); span set to display: none with ER-basis comment.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 10 ER table biomarkers plus the baseline drug-level check from the Monitoring prose are listed.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢

Issues 23/09/2026 12:35

Pass rate 100.00%. No issues found.

Issues 23/09/2026 12:32

1. 1.3 — Standard dose loses attribution: Protocol action_1_value (QRS line 447) presents “1–3 g/day oil or ground seed” as the unattributed standard dose, while the ER (line 421) states “Examine lists 1–3 g/day oil or ground seed” and caps intake at ≤2 g/day for kidney risk (line 409).

Fixes 23/09/2026 12:32

1. 1.3 — Standard dose attribution restored: Changed action_1_sub from “Trials used 1–2 g/day softgels or 2.5–7.5 mL/day liquid” to “Examine range; trials used 1–2 g/day softgels or 2.5–7.5 mL/day liquid”, so the 1–3 g/day figure is attributed to Examine as in the ER.

Issues 23/09/2026 12:28

1. 4.5 — Content exceeds one A4 page: The 7 contraindications, 11 interaction items, 11-row biomarker table with multi-line targets and long protocol sub-lines (lines 450, 461, 472, 541–567, 606–660) render well beyond one A4 page; several cells were not condensed to the per-section budget.

Fixes 23/09/2026 12:28

1. 4.5 — Condensed protocol sub-lines: Shortened action_1_sub (dropped the duplicate ConsumerLab range), action_2_sub (“As in most trials; meals reduce aftertaste and gastrointestinal discomfort”) and action_3_sub (“Seed 1–3 g/day, oil 1–5 mL/day or high-thymoquinone extracts; none compared head to head”).
2. 4.5 — Trimmed gate items: Shortened the kidney threshold to “(eGFR <30)” and the liver threshold to “ALT or AST >3× upper limit of normal”, keeping both; removed hydrochlorothiazide from the blood pressure drug examples because it is already listed under Diuretics.
3. 4.5 — Condensed monitoring cells: Shortened marker_7 target, marker_9 target, marker_10 and marker_11 names and the monitoring cadence line while keeping every biomarker, threshold and interval.

Issues 23/09/2026 12:24

1. 1.3 — “Mild” dropped from digestive risk: The At-a-glance (QRS line 433) says “Concerns include digestive discomfort”, while the ER Conclusion (ER line 525) says “mild digestive discomfort”, which makes the risk sound stronger than the ER does.

Fixes 23/09/2026 12:24

1. 1.3 — Restored “mild” digestive qualifier: Changed At-a-glance “Concerns include digestive discomfort” to “Concerns include mild digestive discomfort” to match the ER Conclusion; shortened “adults who track their numbers” to “adults tracking their numbers” to stay within 70 words.

Issues 23/09/2026 12:22

1. 2.13 / 7.2 — Audience takeaway missing from lede: The at_a_glance text (QRS line 433) omits the ER Conclusion’s execution-oriented, audience-specific takeaway (ER line 525: for health-focused adults who track their own markers, the oil offers small, measurable shifts at low cost), so the lede reads only as general caution.

Fixes 23/09/2026 12:22

1. 2.13 / 7.2 — Audience takeaway added to lede: Rewrote at_a_glance to include the ER Conclusion’s takeaway that adults who track their numbers get small, measurable, low-cost improvements, especially from elevated baselines, keeping it at 70 words.

Issues 23/09/2026 12:17

1. 1.3 — Severe skin reactions softened: The At a Glance summary (line 433) says “topical skin reactions” where the ER Conclusion says “severe skin reactions after topical use”, dropping the severity qualifier.

Fixes 23/09/2026 12:17

1. 1.3 — Severe skin reactions restored: Changed “topical skin reactions” to “severe topical skin reactions” in At a Glance, and removed “many” from “many small human trials” to keep the lede at 70 words.

Issues 23/09/2026 12:13

1. 7.2 — Incomplete main-concerns list: Line 433 closes with ‘Main concerns are digestive discomfort, rare kidney and liver injury, and drug interactions’, omitting the ‘severe skin reactions after topical use’ that the ER Conclusion (line 525) names among the main safety considerations.

Fixes 23/09/2026 12:13

1. 7.2 — Incomplete main-concerns list: Replaced “Main concerns are digestive discomfort, rare kidney and liver injury, and drug interactions” with “Concerns include digestive discomfort, rare kidney and liver injury, topical skin reactions and drug interactions”; trimmed “dietary” and “body” earlier in the lede to keep it at 70 words.

Issues 23/09/2026 12:09

1. 14.2 — Anti-TPO antibodies omitted: The ER Monitoring table pairs TSH with anti-TPO antibodies (“pair with anti-TPO antibodies”), but the QRS marker_11 row (line 657) lists only TSH.

Fixes 23/09/2026 12:09

1. 14.2 — Anti-TPO antibodies added: Renamed the marker_11 row from “TSH (thyroid autoimmunity only)” to “TSH and anti-TPO antibodies (thyroid autoimmunity only)”, matching the ER Monitoring table.

Issues 23/09/2026 12:07

1. 14.2 — Urea missing from markers: The ER Monitoring section lists urea in the baseline kidney panel (“creatinine, eGFR, urea”, ER line 477; “pair with urea”, ER line 489), but the QRS marker table omits it (marker_7_name at QRS line 637 reads only “Creatinine and eGFR”).

Fixes 23/09/2026 12:07

1. 14.2 — Urea added to markers: Changed marker_7_name from “Creatinine and eGFR” to “Creatinine, eGFR and urea” so the urea listed in the ER Monitoring baseline kidney panel is included.

Issues 23/09/2026 12:04

1. 4.3 — Monitoring labels paraphrased: marker_7_name “Creatinine and eGFR (with urea)” (line 637) and marker_11_name “TSH and anti-TPO antibodies (thyroid autoimmunity only)” (line 657) alter the ER table labels “Creatinine and eGFR” and “TSH (thyroid autoimmunity only)” (ER lines 489, 492).

Fixes 23/09/2026 12:04

1. 4.3 — Monitoring labels restored verbatim: Changed marker_7_name from “Creatinine and eGFR (with urea)” to “Creatinine and eGFR” and marker_11_name from “TSH and anti-TPO antibodies (thyroid autoimmunity only)” to “TSH (thyroid autoimmunity only)”, matching the ER table labels.

Issues 23/09/2026 12:02

1. 12.3 — Magnitude qualifier in benefit: benefits_high (QRS line 522) reads “modest weight and waist reduction”; “modest” is an effect-size qualifier that Benefits items must not carry.

Fixes 23/09/2026 12:02

1. 12.3 — Magnitude qualifier removed: Changed benefits_high item “modest weight and waist reduction” to “weight and waist reduction”.

Issues 23/09/2026 11:57

1. 7.2 — At-a-glance omits safety considerations: The at_a_glance text (line 433) covers only the evidence verdict from the ER Conclusion and leaves out its main safety considerations (digestive discomfort, rare kidney and liver injury, drug interactions), so it is not an execution-oriented summary.

Fixes 23/09/2026 11:57

1. 7.2 — At-a-glance safety considerations added: Tightened the at_a_glance wording and added the ER Conclusion’s main safety considerations (“Main concerns are digestive discomfort, rare kidney and liver injury, and drug interactions.”), keeping it at 70 words.

Issues 23/09/2026 11:56

1. 8.4 — Rationale kept in contraindication: The pregnancy/breastfeeding contraindication (line 542) retains the explanatory parenthetical “(no safety data)”, which is a rationale rather than a qualifier.
2. 14.2 — Anti-TPO antibodies missing: The ER Monitoring section pairs TSH with anti-TPO antibodies (ER line 492), but the QRS Monitoring table (lines 657-659) omits anti-TPO antibodies.

Fixes 23/09/2026 11:56

1. 8.4 — Rationale removed from contraindication: Changed “Pregnant women (all trimesters) and breastfeeding women (no safety data)” to “Pregnant women (all trimesters) and breastfeeding women”, dropping the explanatory parenthetical.
2. 14.2 — Anti-TPO antibodies added: Renamed marker_11 from “TSH (thyroid autoimmunity only)” to “TSH and anti-TPO antibodies (thyroid autoimmunity only)” and set its target to “TSH 1.0–2.5 mIU/L”, since the ER gives no anti-TPO target.